尿液NMP22、OPN及BTA检测在膀胱尿路上皮癌诊断和预后评估中的价值

doi:10.19558/j.cnki.10-1020/r.2020.03.011

摘要
图/表
参考文献
相关文章 (11)

全文: PDF (1192 KB) RICH HTML
输出: BibTeX | EndNote (RIS)

摘要 目的： 探讨尿液核基质蛋白22（NMP22）、骨桥蛋白（OPN）及膀胱肿瘤抗原（BTA）检测在膀胱尿路上皮癌诊断和预后评估中的价值。方法： 选取65例膀胱尿路上皮癌患者为观察组,49例泌尿系统良性疾病患者为良性组,45例健康体检者为健康组。检测三组患者尿液NMP22、OPN及BTA水平,并分析其检测结果对膀胱尿路上皮癌的诊断价值,探讨不同临床特征患者NMP22、OPN及BTA阳性率差异,对比不同NMP22、OPN及BTA表达情况患者3年生存情况。结果： 观察组患者尿液NMP22、OPN及BTA水平均显著高于良性组和健康组（P<0.05）。NMP22、OPN及BTA诊断膀胱尿路上皮癌的曲线下面积分别为0.898、0.887、0.878,联合检测的受试者工作特征曲线下面积为0.957,诊断敏感度为92.5%,特异度为87.2%。尿NMP22、OPN及BTA的表达与肿瘤直径、肿瘤数目、病理分级、临床分期、有无淋巴结转移有关（P<0.05）;而与患者性别、年龄无关（P>0.05）。NMP22、OPN及BTA表达阳性患者生存率均显著低于阴性患者（P<0.05）。结论： NMP22、OPN及BTA对膀胱尿路上皮癌的诊断具有潜在价值,其表达情况与临床病理特征以及预后存在相关性。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	朱有森
	李艳红
	宋光鲁

关键词 ：尿路上皮癌, 核基质蛋白22, 骨桥蛋白, 膀胱肿瘤抗原

Abstract：Objective： To explore the value of urine nuclear matrix protein 22 (NMP22), osteopontin (OPN) and bladder tumor antigen (BTA) in the diagnosis and prognosis of bladder urothelial carcinoma. Methods： Sixty-five patients with bladder urothelial carcinoma were selected as observation group, 49 patients with benign diseases of urinary system as benign group, and 45 healthy subjects as healthy group. The levels of urine NMP22, OPN and BTA in three groups were determined, and the diagnostic value of NMP22, OPN and BTA in bladder urothelial carcinoma was analyzed. The differences in NMP22, OPN and BTA positive rate in patients with different clinical characteristics were investigated, anUrine NMP22, OPN and BTA levels in observation group were significantly higher than those in benign and healthy groups (P < 0.05). The AUC of NMP22, OPN and BTA in the diagnosis of bladder urothelial carcinoma was 0.898, 0.878 and 0.887, respectively. The AUC of combined detection was 0.957, with sensitivity of 92.5% and specificity of 87.2% respectively. The expression levels of NMP22, OPN and BTA in urine were correlated with tumor diameter, tumor number, pathological grade, clinical stage and lymph node metastasis (P < 0.05), and not with gender and age (P > 0.05). The survival rate of patients with positive expression of NMP22, OPN and BTA was significantly lower than that of patients with negative expression (P < 0.05). Conclusion： NMP22, OPN and BTA have potential values in the diagnosis of bladder urothelial carcinoma. The expression levels of NMP22, OPN and BTA are correlated with clinicopathological features and prognosis.

Key words： urothelial carcinoma nuclear matrix protein 22 osteopontin bladder tumor antigen

收稿日期: 2019-04-24

ZTFLH:

R737.1

通讯作者: 宋光鲁,1093975593@qq.com

引用本文:

朱有森, 李艳红, 宋光鲁. 尿液NMP22、OPN及BTA检测在膀胱尿路上皮癌诊断和预后评估中的价值[J]. 微创泌尿外科杂志, 2020, 9(3): 203-207.
ZHU Yousen, LI Yanhong, SONG Guanglu. Value of urine NMP22, OPN and BTA in diagnosis and prognosis of bladder urothelial carcinoma. JOURNAL OF MINIMALLY INVASIVE UROLOGY, 2020, 9(3): 203-207.

链接本文:

http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/abstract/abstract1598.shtml 或 http://journal20.magtechjournal.com/Jwk_zgmnwk/CN/Y2020/V9/I3/203

[1] BABJUK M, BÖHLE A, BURGER M, et al. EAU guidelines on non-muscle-invasive urothelial carcinoma of the bladder: update 2016. Eur Urol, 2017,71(3):447-461.
[2] FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer, 2015,136(5):E359-E386.
[3] 瞿根义,林民毅,许宁,等.Paxillin在膀胱尿路上皮癌组织中表达情况与淋巴结转移及生存预后的关系.临床泌尿外科杂志,2017,32(12):948-953.
[4] 赵言廷,郭晓慧,白晶,等.荧光原位杂交技术在尿路上皮癌辅助诊断中的应用价值.中国实验诊断学,2016,20(9):1522-1524.
[5] 孟占鳌,何娅娣,夏桃林,等.MR扩散加权成像对膀胱尿路上皮癌的诊断价值.中华腔镜泌尿外科杂志(电子版),2017,11(6):404-406.
[6] NAKAMURA Y, YOSHIDA S, TANAKA H, et al.Potential utility of diffusion-weighted magnetic resonance imaging in diagnosis of residual bladder cancer before second transurethral resection. Urol Int, 2017,98(3):298-303.
[7] 黄卓雅,陈桂青,张耀忠,等.Survivin、XIAP及Caspase-3在膀胱乳头状尿路上皮癌组织中的表达及临床意义.华中科技大学学报(医学版),2018,47(1):91-95,120.
[8] 江明友,万明发,洪钟亮.尿液BLCA-4与BLCA-1水平在膀胱癌诊断及复发检测中的价值.中华全科医学,2018,16(4):570-572.
[9] 柳家园,彭翔,宁向辉,等.尿脱落细胞荧光原位杂交检查阳性在尿路上皮癌中的临床价值.北京大学学报(医学版),2017,49(4):585-589.
[10] 朱金锋. 尿液标志物诊断膀胱癌的研究进展.癌症进展,2018,16(8):935-939.
[11] 吕天兵. 核基质蛋白22、细胞角质素20和存活素mRNA对膀胱癌诊断价值的研究.国际检验医学杂志,2017,38(18):2551-2553.
[12] 李志斌,陈惠庆,米振国,等.肾盂尿路上皮癌患者尿NMP22、TPS、CYFRA21-1、CA19-9的检测与评估.现代泌尿生殖肿瘤杂志,2016,8(4):204-211.
[13] 闫小晨,张连栋.血清血管内皮生长因子和骨桥蛋白水平对膀胱癌淋巴转移的影响.解放军预防医学杂志,2016,34(5):715-717.
[14] 周逢海,李海元,吕海迪,等.血清及尿液OPN对膀胱尿路上皮癌的诊断及临床意义的研究.临床泌尿外科杂志,2016,31(11):982-985.
[15] 刘莉,杨永姣,龙安安,等.尿液5种肿瘤标记物联合检测对膀胱癌的诊断价值.山东医药,2018,58(10):75-78.
[16] 丁丽丽,黄玲莎,叶俭,等.尿膀胱肿瘤抗原在膀胱癌中的表达及意义.中国现代医学杂志,2017,27(6):106-109.